Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for iron deficiency anemia in obstetric and gynecologic patients
Authors:
- Hye Won ShinHSHye Won Shin
- Doo Yeon GoDGDoo Yeon Go
- Suk Woo LeeSLSuk Woo Lee
- Yoon Ji ChoiYCYoon Ji Choi
- Eun Ji KoEKEun Ji Ko
- Hae Sun YouHYHae Sun You
- Yoo Kyung JangYJYoo Kyung Jang
Open Access
- 21 May 2021
- journal article
- review article
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (20) , e24571
Abstract
Introduction: Iron deficiency anemia (IDA) is common among obstetric and gynecologic patients. This systematic review aimed to assess the comparative efficacy and safety of commonly used intravenous (IV) iron formulations, ferric carboxymaltose (FCM), and iron sucrose (IS) in the treatment of IDA in obstetric and gynecologic patients. Methods: We systematically searched PubMed, EMBASE, Cochrane CENTRAL, and Google Scholar for eligible randomized controlled trials (RCTs) comparing IV iron replacement using FCM and IS up to October 2019. The primary outcome was to compare the efficacy of FCM and IS, assessed by measuring serum hemoglobin (Hb) and ferritin levels before and after iron replacement. The secondary outcome was to compare the safety of FCM and IS, assessed by the incidence of adverse events during iron replacement. The meta-analysis was performed using RevMan 5.3. Results: We identified 9 RCTs with 910 patients (FCM group, n = 456; IS group, n = 454). Before iron replacement, FCM and IS group patients had similar baseline Hb (mean difference [MD], 0.04 g/dL; 95% confidence interval [CI], −0.07 to 015; I 2 = 0%; P = 0.48) and ferritin levels (MD, −0.42 ng/mL; 95% CI, −1.61 to 0.78; I 2 = 45%; P = 0.49). Following iron replacement, patients who received FCM had higher Hb (MD, 0.67; 95% CI, 0.25–1.08; I 2 = 92%; P = 0.002) and ferritin levels (MD, 24.41; 95% CI, 12.06–36.76; I 2 = 75%; P = 0.0001) than patients who received IS. FCM group showed a lower incidence of adverse events following iron replacement than IS group (risk ratio, 0.53; 95% CI, 0.35–0.80; I 2 = 0%; P = 0.003). Serious adverse events were not reported in any group. Conclusion: FCM group showed better efficacy in increasing Hb and ferritin levels and a favorable safety profile with fewer adverse events compared with IS group for IDA treatment among obstetric and gynecologic patients. However, this meta-analysis was limited by the small number of RCTs and high heterogeneity. Trial registration: The review was prospectively registered with the International Prospective Registry of Systematic Reviews (https://www.crd.york.ac.uk/prospero/, registration number CRD42019148905).Keywords
This publication has 40 references indexed in Scilit:
- FERGIcor, a Randomized Controlled Trial on Ferric Carboxymaltose for Iron Deficiency Anemia in Inflammatory Bowel DiseaseGastroenterology, 2011
- Assessment of iron status in US pregnant women from the National Health and Nutrition Examination Survey (NHANES), 1999–2006The American Journal of Clinical Nutrition, 2011
- A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patientsNephrology Dialysis Transplantation, 2010
- A prospective randomized, controlled trial of intravenous versus oral iron for moderate iron deficiency anaemia of pregnancyJournal of Internal Medicine, 2010
- Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indicationsArzneimittelforschung, 2010
- Ferric Carboxymaltose in Patients with Heart Failure and Iron DeficiencyNew England Journal of Medicine, 2009
- BLOOD MANAGEMENT: Large‐dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trialTransfusion, 2009
- Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemiaInternational Journal of Gynecology & Obstetrics, 2008
- Intravenous Ferric Carboxymaltose Compared With Oral Iron in the Treatment of Postpartum AnemiaObstetrics & Gynecology, 2007
- Iron, anaemia, and inflammatory bowel diseasesGut, 2004